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ABSTRACT 
Development of a real-time PCR assay for detection of hepatitis B virus 1762T/1764A double mutation for 
the screening of Hepatocellular Carcinoma 
Selena Lin 
Dr. Ying-Hsiu Su 
 
 
 
 
The 1762T/1764A double mutation of the hepatitis B virus (HBV) located in the basal core promoter of the 
HBV genome, has been suggested to be a potential biomarker for hepatocellular carcinoma (HCC) among 
individuals with chronic HBV infection. Previously, we have demonstrated that urine contains fragmented, 
low molecular weight (300 bp in size) DNA from the body circulation of fluids and can be used for cancer 
detection. The ultimate goal of this experimental investigation is to explore the potential to develop an 
assay for the detection of this HBV double mutation associated with HCC with future works in the area of 
applying this assay for urine testing.  Here, we developed an ultra-sensitive real-time PCR assay suitable 
for utilizing low molecular weight substrate by using hybridization probes and an oligonucleotide clamp 
containing locked nucleic acids (LNAs). Hybridization probes provide melting curve analysis capabilities 
which eliminate post-PCR manipulation and minimize the human error handling to a one-step process. 
Labor and time was minimized to less than two hours per assay run. The LNA-containing oligonucleotide 
clamp was specific for the wild type HBV and demonstrated the ability to suppress the amplification of the 
wild type HBV templates and inhibit the binding of the WT templates to the fluorescence probes. As a 
result, the detection of HBV double mutation was made possible in the presence of 3000-fold excess of the 
wild type genome through the use of post-PCR melting curve analysis capabilities; an improvement from 
the detection of 20 fold excess wild type genome.  Thus, this assay can potentially be used in a real-time 
PCR based urine test for HCC screening. Overall, PCR amplification coupled with the melting curve 
analysis generated a quick, simple, and highly sensitive tool for the detection of this HBV double mutation.  
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I. INTRODUCTION 
 
 
 
  1.1 Hepatocellular Carcinoma   
 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of 
cancer morbidity worldwide. There are over 600,000 new cases each year and over 250,000 deaths in 
geographic regions of Asia and sub-Saharan Africa alone and up to 800,000 deaths worldwide [1-4]. The 
etiology of liver cancer is believed to be multifactorial and complicated in high risk regions by interplay 
between environmental chemical agents and hepatitis virus infections.   
 
The major risk factor for HCC is chronic infection with Hepatitis B virus (HBV) [2, 5-9]. HBV has been 
associated with 70 to 80% of HCC worldwide [5, 7, and 8].  Also, the annual incidence of HCC ranges 
from 1 to 6% of patients with chronic hepatitis varying increasingly with age [6, 9]. Liver cirrhosis has also 
been associated with the incidence of HCC ranging approximately 2.5% yearly in patients and 60-80% of 
people with HCC also have cirrhosis. The molecular mechanisms by which HBV induce HCC remains 
unclear [6, 8, 9].  Among them, certain HBV mutations may also participate in the tumorigenesis process 
[6, 10-12].  
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Figure 1. Global Mapping of Hepatitis B Carriers and Incidence in 2004. 
These two maps show the similarities between the geographical distributions of chronic hepatitis B virus 
infection and hepatocellular carcinoma incidents in 2004[12, 13].  
 
 
 
The prognosis for HCC is very poor and most studies have reported a 5-year survival rate of less than 5% 
due to late detection [4, 12, 14-16]. Although HBV vaccination has been effective in preventing new 
infections, HCC cases have been on the rise in this country [3, 7, and 17]. Surgical resection remains to be 
the best option for treatment only when HCC is diagnosed early.   
 
1.2 Current detection of Hepatocellular Carcinoma 
 
The current methods of screening are not specific or sensitive in diagnosing HCC. The primary types of 
detection involve serological and/or radiological tests. One of the first available screening tests involves the 
alpha-fetoprotein (AFP) [9]. Alpha-fetoprotein is a plasma protein that occurs in low yet detectable levels 
in normal human adults. In the presence of tumors, the levels have been suggested to increase and act as a 
cancer biomarker for HCC. This test is sufficient for detecting larger tumors but is less sensitive and 
ineffective in detecting small lesions between 1 and 3cm. Up to 40% of HCC cases are negative for AFP. In 
addition to AFP’s low predictive value, this test showed that some results may have been caused by non-
malignant physiological events [3, 18, 19].  Also of interest is the AFP-L3, glysosylated AFP and des-
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gamma-carboxy-prothromin (DGCP). Both have shown poor sensitivity and specificity to HCC. DGCP has 
been suggested to be a marker for portal vein invasion which would be a poor surveillance test as it 
identifies late diseases rather than early diseases [9, 19].    
 
The most widely used radiological test is ultrasonography (US) which also has low sensitivity and also 
requires a tumor size of at least 3cm, but ultrasound demonstrates high specificity >90%[9]. However, US 
is expensive thus is not effective for frequent use.  In addition, US use is dependent on trained physicians 
and operators. Other radiological tests include abdominal computed tomography (CT) and magnetic 
resonance imaging (MRI). They are sensitive (minimal tumor size is 2 cm) and highly specific.  However, 
the high cost and/or significant radiation exposure prevents their use as screening tools. They are currently 
used only for diagnostic purposes [18, 20]. Thus, the lack of effective screening results not only 
demonstrates the need but also the advantage in developing an effective screening protocol to detect HCC 
at an early stage.   
 
Screening for certain cancers at an early stage has been estimated to increase survival in up to 50% of 
patients, yet such reliable, cost-effective screening methods are not available for numerous cancers such as 
lung and ovarian cancer[21-23].  Undergoing screening during the early stages of HCC will significantly 
improve the chances of receiving effective treatment and ensuring survival[24].  
 
1.3 HBV Double Mutation 1762T/1764A 
 
The possibility of presenting a screening method for HBV-related HCC with increased specificity and 
sensitivity begins with detecting HCC-related HBV genomic variants. A known mutation associated with 
HCC is the 1762T/1764A double mutation located in the basal core promoter region. This mutation 
comprised of adenine-1762 to thymine transversion and guanine-1764 to adenine transition (1762T/1764A) 
has been found in 50-85% of HCC tumor tissues [5, 12, 25-30]. This mutation belongs to the basal core 
promoter region appearing to have greater clinical relevance in the developing tumorgenesis of HCC[31]. 
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The first mutation converts the amino acid 130 from lysine (AAG) to methionine (ATG) (1762 AÆT, 
AAG ÆATG) which replaces a charged amino acid to a hydrophobic. The second mutation converts 
valine(GTC) to isoleucine(ATC) (1764 GÆA , GTCÆATC).  
 
 
 
 
Figure 2.  HBV WT and HBV 1762T/1764A DNA sequences from GenBank #X04615. 
WT denotes the wild-type DNA sequence and Dm denotes the HBV double mutation 1762T/1764A DNA 
sequence 
 
 
  
The amino acid characteristics suggest why the mutation at 1762 rarely occurs alone [27]. The double 
mutation falls within the loop of the disulfide linkage between cysteine-61 and cysteine-137. These changes 
could alter the structure of the X protein and appear to be associated with enhanced viral replication, 
increased severity of liver inflammation, which may ultimately increase the risk of HCC [25, 27, 29, 30, 
32-34].  The onset of this double mutation relationship with HCC can be utilized to detect the increasing 
progression of HBV infection and HCC resulting from HBV infection. Thus, the detection of 1762T/1764A 
double mutation may be useful as a potential biomarker for HCC in long term HBV-carriers 
 
1.4 Current Detection of HBV Double Mutation 1762T/1764A 
 
Studies have shown that tumors can release their DNA into plasma/serum, and can be subsequently 
detected there. [35-37].  The mechanism as to which DNA becomes secreted into the bloodstream is 
unknown, but the hypothesis of cancer cell apoptosis shedding nuclear DNA has been suggested. This has 
led to an increasing interest in detecting the small size modified DNA through a non-invasive method that 
is not restricted by sample volume and can be readily performed. Recent studies have showed promising 
evidence of utilizing PCR based detection of extracellular tumor-derived circulation DNA [38-42]. The 
detection of this double mutation can be obtained through PCR amplification of the target sequence 
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followed by direct DNA sequencing,  PCR analysis can  also be followed by restriction enzyme (Sau3AI) 
digestion (restriction fragment length polymorphism RFLP), mismatched PCR coupled with RFLP, or short 
oligonucleotide mass spectra analysis (SOMA) [29, 30, 43] . However, RFLP is a slow process that 
requires large amounts of DNA in addition to the processes of probe labeling, DNA fragmentation, 
electrophoresis, blotting, hybridization, washing, and autoradiography. These methods present obstacles 
such as too labor intensive, time-consuming, or insensitive due to the interference by the excessive wild 
type (WT) HBV DNA molecules in the sample.  The methods that utilize mass spectra analysis have a limit 
in distinguishing two bands that differ by 20-fold in intensity. The direct DNA sequencing and restriction 
fragment length polymorphism approach require 5-20% total viral population to be mutants. Thus, these 
current detection methods may not be sensitive enough to detect the HBV double mutation in body fluids 
such as blood or urine. Another obstacle that makes the detection of the double mutation difficult deals 
with the nature of the HBV virus. High errors in replication can be attributed to the genome replication 
process, environmentally induced mutations, and recombination [31, 44]. The reverse transcriptase fidelity 
that produces high error rates in the HBV genome is a major contributor in the replication process. Also, 
HBV mutants tend to develop insidiously into the dominant virus. This presents a prominent need for an 
improved effective, sensitive, and specific detection method of the HBV double mutation to account for 
mutations within the dominant wild-type virus. 
 
An effective early detection method can save up to 598,000 lives to liver cancer [45]. Implementing a 
sensitive and specific screening method for early detection can contribute to reducing the morbidity and 
mortality caused by HCC [17].  Many studies have shown substantial improvement in survival when 
patients utilize early detection over none. Yet, the current methods for screening involving assessments 
such serum liver function tests and AFP are not only ineffective but may also be painful and costly 
resulting in low compliance. Also U/S and CT scans can be costly and are prohibitive in routine use. By 
developing an early detection method that incorporates overcoming the obstacles of screening and detecting 
HBV double mutation, an alternative screening approach can ensue. This will provide an approach such 
that is non-invasive, non restrictive by sample volume to help increase compliance rates for screening and 
reduce the consequences of HCC. The detection of circulating DNA in biological fluids can be an 
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opportunistic tool as a molecular tumor marker and potential profiling tool that benefits cancer patient 
survival and can increase in quality of life.  
 
The ultimate purpose of this investigation is to improve the prognosis of HCC through the urine-based 
early detection screening including the detection of the HBV double mutation 1762T/1764A marker. In 
order to accomplish this goal, an assay that is suitable to detect circulating DNA will need to be developed. 
This study will aim to develop an assay to detect the HBV double mutation 1762T/1764A due to its 
association with HCC.   
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II. DESIGN OUTLOOK 
 
 
 
2.1  Design Criteria 
 
This experimental design will be focused on overcoming current obstacles in detection of HBV 
1762T/164A which is through DNA sequencing or RFLP with a sensitivity ratio higher than the current 
mutant to wild-type ratio (1:20). Thus, the assay detection required will need to be sensitive enough to 
detect such low levels of DNA (at least 100 copies) as well as effective enough to distinguish the short 
HBV double mutation DNA substrate in the presence of other mutations and the wild-type sequence. The 
minimal labor and time should be no more than one day and human handling should be minimized from 
two or more step process to a one step process.  
 
2.2  Real­Time PCR Approach 
 
By understanding previous methods used in screening for the HBV genome, opportunities can be taken to 
bypass the obstacles that were previously encountered.  The current detection of HBV genomic variants 
involve quantitative polymerase chain reaction (qPCR) also known as real-time polymerase chain reaction. 
qPCR is an increasingly used molecular method for quantification and subsequent detection of viral 
genomes [46, 47]. qPCR method can be utilized to amplify target sequences with appropriate primers, 
probes, polymerases, etc. Like the conventional PCR, the cycling steps involved are heating a sample to 
denature the DNA, cooling slightly to allow for annealing to respective primers, and then raising the 
temperature to promote extension of the double strand DNA. This is repeated in cycles until a desired 
quantity of the target sequence is amplified.  
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Figure 3. Polymerase Chain Reaction (PCR). 
These steps show the three cycles that occur in the PCR reaction. The first denaturing step is responsible to 
melt the double stranded DNA in separate single strands. The mixture is then cooled in order for the 
primers to find the nucleic acid complementary regions and anneal. Then the mixture is heated in order for 
the polymerase to replicate and extend the strand. 
 
 
 
In previous studies of detecting HBV mutations, conventional PCR analysis methods involved performing 
digestion of DNA fragments with restriction enzymes and subsequent electrophoresis of agarose gels or 
polyacrylamide gels. This requires post amplification manipulation and increases variable contamination 
factors. An approach to overcome this labor intensive and time consuming method is to involve real-time 
monitoring during the qPCR that provides PCR product analysis without the post PCR analysis procedures. 
 
2.3  Fluorescence Resonance Energy Transfer (FRET) 
 
One of the easiest ways to implement real-time monitoring is through use and monitoring of fluorescence 
during qPCR. The use of double strand-specific dye, SYBR Green I can be used or fluorescently labeled 
oligionucletoide probes such as TaqMan®, or hybridization probes. Hybridization probes provide a further 
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advantage in the measurement of the probe melting temperature. This is essentially useful for mutation 
detection as specific as a single base pair. These modified short DNA oligonucleotide probes fluoresce 
when hybridized with a complementary DNA segment during qPCR. This fluorescence describes the 
mechanism, fluorescence resonance energy transfer (FRET), a distance dependent interaction between the 
electronic excited states of two dye molecules.  
 
These probes typically emit reduced quantities of fluorescence when isolated, but when hybridized to their 
complementary target sequences, fluorescence is emitted. The amount of fluorescence that is emitted 
during each cycle of qPCR can be quantified for the real time accumulation of the amplicon and 
determination of whether a specific sequence is present or not (see Figure 4)  [31, 48]. One can design a 
probe that is complementary to a target template. Thus, this hybridization mechanism is especially useful in 
the investigations of small scale DNA regions and in detecting nucleic base mutation. This process involves 
oligonucleotides probes that opportune a fast and effective means in accessing genetic variations [49].  
Thus, incorporating oligonucleotide probes during real time PCR opportune an improved faster, more rapid 
process simultaneously minimizing variable contamination factors [31, 47].  
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Figure 4. Fluorescence of oligonucleotide probe Mechanism 
This figure labels oligonucleotide probe with a 5’ end labeled R, the reporter probe, and the 3’ end labeled 
Q, the quencher probe. In consistency with the FRET mechanism, the quencher when in proximity to the 
reporter greatly reduces the fluorescence of the reporter. However once the probe is hybridized during the 
annealing step, the extension phase will eventually be cleave by the 5’ polymerase activity and 
fluorescence is emitted. This does not interrupt the overall PCR process and results in an increase of 
fluorescence intensity that is proportional to the amount of amplicon produced[50]. 
 
 
 
 
2.4  Melting Curve Analysis 
 
The post-PCR analysis that oligonucleotides probes are capable of are melting curve analysis. Melting 
curve analysis is a robust and well established method to detect mutations including single base pair 
changes.  The shape and position of the DNA melting curve is dependent on the length, sequence, and 
GC:AT ratio[47].  Numerous melting techniques use fluorescently labeled oligonucleotide probes to detect 
short segments of the PCR product[51].  Melting curves can be converted to negative first-derivative 
melting plots. This reveals the melting transitions of the probe-target hybrids as curve peaks. Samples that 
display a single peaks signify a homozygous genotype, and those with 2 peaks indicate a heterozygous 
genotype. To perform the melting curve analysis, the temperature is raised to allow the probes to dissociate 
from the DNA template resulting in the loss of the FRET signal. Any mis-match between the probes and 
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DNA template will cause the dissociation to occur earlier (Figure 5). This dissociation can be detected 
through a shift in Tm curve and this provides distinction between a mutant and a wild-type template. 
 
 
 
 
Figure 5. Schematic display of fluorescent melting curve analysis for genotyping[50] 
 
 
 
A mismatched base usually causes a temperature shift between 5-9°C[50].  For greater specificity, shorter 
probes can be used (<25bps). The intensity of the FRET signal depends on the optimal probe/template 
ratio, salt concentrations, etc. The melting peak areas do not always indicate the amount of the target 
sequence present. This includes the different efficiencies of the probe binding. Thus, positive controls and 
wild type controls should be included in the qPCR run to confirm whether the sample contains a mutation 
or not.    
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2.5  Roche Light Cycler® 2.0 Real­Time PCR Instrument 
 
This system is a carousel based thermal cycler platform (Figure 6; panel B) with a fluorescence detection 
system. This system utilizes true melting curve analysis, automated absolute quantification, and 
hybridization probes.  The reaction volume is inserted into a glass capillary tube that provide optimal 
surface to volume ratio to allow rapid equilibrium between the air and reaction components (Figure 6; 
panel A). These capillaries avoid contamination with the tightly closed cap that does not need to be 
removed during analysis. The software provided presents easy to analyze results through post-PCR analysis 
tools. Thus, the development of this assay will utilize this instrument to perform qualitative assay runs on 
various probes/primers and subsequent automated melting curve analysis for a fast turnover and quick 
results.   
 
 
 
 
 
Figure 6. Design and Mechanism for LightCycler® 2.0 Instrument. 
Panel A displays the design of the LightCycler® system. The sample is inserted into the carousel and 
detection occurs through the LED light source. Panel B displays the cylindrical chamber where the samples 
placed inside are warmed by a heating coil. Pointer 1 denotes the detection unit of blue LED light source 
which has three detection channels. Pointer 2 denotes the carousel that holds the glass capillaries (holds 
20µl) that enable a high surface to volume ratio during rapid cycles ( http://www.roche-applied-
science.com/sis/lightcycler/images/) 
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2.6  Optimization/Modifications Options 
 
2.6.1 Primers and Probes 
 
Efficiency during qPCR depends on the selection of primers and probes. Primers were designed on Vector 
NTI software. This was to ensure that primers do not form false priming sites, primer dimers which can 
occur when primers contain complementary sequences to each other, and primer/probe hybrids. Efficient 
hybridization/binding of probe overcomes competition with primer extension and product re-annealing 
through various methods. Because the binding of the probe to the target is reversible, a PCR reaction mix 
should contain a higher concentration of probe-to-primer to promote saturation of the binding site. The 
probe should be designed with a higher Tm (5-10°C) in order to bind first to the single strand target during 
the competitive annealing cycle as the temperature begins to cool. Yet, probes temperatures should not be 
higher than the extension temperature otherwise it will inhibit polymerase extension. Probes should also be 
designed to bind to the target with greater affinity than primers. Primer melting temperatures should also be 
considered when choosing the probe.  
 
 
2.6.2 Locked Nucleic Acids (LNA) 
 
A recent tool used for increasing sensitivity in detection of nucleic acid is a nucleic acid analogue, locked 
nucleic acids (LNA)[52]. In previous studies, they have been used in PCRs as a WT-mediated clamp to 
suppress the amplification of WT in a given sample thus enhancing the detection of the mutant DNA [52, 
53] . They form duplexes with sequence specific complementary DNA and increase the thermal stabilities 
without interrupting sequencing thus improving selectiveness[54, 55].  LNA is a synthetic RNA/DNA 
derivative with a ribose moiety in the sugar –phosphate backbone that is “locked” and thus structurally 
constrained. The methylene linkage between the 2’ oxygen and the 4’ carbon is constrained. The modified 
probes are short in length and have high binding affinity. Thus, the use of LNA presents the opportunity to 
exploit its clamping characteristics and increase PCR sensitivity. The use of LNA will be tested in this 
assay design. 
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Figure 7. Locked Nucleic Acid chemical structure diagram. 
This is novel type of nucleic acid analog that contains a 2’-O, 4’-C methylene bridge.  The bridge-locked in 
3’endo conformation restricts the flexibility of the ribofuranose ring thus locking the structure into a rigid 
bicyclic formation. This enables stronger and more stable binding.  
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III. REAGENTS 
 
 
The following items were commercially available laboratory materials used throughout the daily 
procedures of this research project.  Please note the materials are stored at room temperature. 
General Reagents/Stocks 
Diethylpyrocarbonate (DEPC) treated water (Ambion®, Inc) 
Nusieve® 3:1 Agarose (Lonza Group, Ltd) 
1% Ethidium Bromide (Fisher Scientific, Bio-Rad) 
100kb DNA ladder (BioLab, Inc)  
LB Broth, Miller (Difco ™) 
 
Buffers 
1x TAE buffer 
Tris Acetic Acid, Ethylenediamine, Tetraccetic Acid, pH 8 
10x Sample Loading Buffer 
30% (w/v) glycerol, 5mM EDTA, 0.05% (w/v) bromophenol blue, pH 7.5 
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IV. METHODS 
 
4.1 Primers/Oligonucleotides Preparation 
 
Primers were prepared using Vector NTI software. Primers were purchased from Sigma-Aldrich® (St. 
Louis, MO) unless noted otherwise. To prepare the primers for use, the air dried samples were spin briefly 
to ensure the contents are concentrated at the bottom of the tube. The appropriate amount of DEPC H2O 
was added to produce 0.1 mM stock concentration. The stock was set aside and a ready –to- use 
concentration (10µM, 20 µM, etc) was prepared in a new 1.5ml tube. All stock and prepared 
oligonucleotides were stored at -20°C.  This will ensure minimal defrost/exposure of the primers and 
probes that are not in use. 
 
 
 
 Table 1. Primer Sequences and the Tm of each oligonucleotide 
Primer Name Tm(°C) Sequence(5’-3’) 
HBVdmSeqFwd(1L) 62.4 CCCAAGGTCTTACACAAGAGG 
HBVdmSeqRev(1R) 63.9 GGAAAAAGTTGCATGGTGCT 
LCFwd 63.5 CCGACCTTGAGGCATACTTC 
LCRev 62.4 AAGGTGCATGGTGCTGG 
Cloning Standards Tm(°C) Sequence(5’-3’) 
17624dm5 64.7 TTAGGTTAATGATCTTTGTACTAGGAGGCT 
7624dm3 61.2 GTACAAAGATCATTAACCTAATCTCCTC 
1762T5 66.2 ATTAGGTTAATGGTCTTTGTAC  
1762T3 73 TAGAAAGACCATTAACCTAATCTAGGAGGCTTCCTCCCCCA 
1764A5 64.9 GGTTAAAGATCTTTGTACTAGGAGGCTG 
1764A3 60.6 GTACAAAGATCTTTAACCTAATCTCCTC 
T3 56.7 TTAATACGACTCACTATGGGC 
T7 50.8 CCCTTTAGTGAGGGTTAATT 
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Table 2. Probe Sequences and the Tm of each oligonucleotide 
Oligonucleotide Tm(°C) Sequence (5’-3’) 
WT-specific 
LNA Clamp* 
38.7 GGt tAa AGG TcT TtG t-NH;  
 
Sensor* 64.1 gag att agg tta atg atc ttt gta cta gg 
Anchor* 56 LCRed640-ggc tgt agg cat aaa ttg gtc tgt tca-PH 
This table displays the probe DNA sequence in the 5’ to 3’ direction. The LNA monomers are indicated in 
upper case letters (16mer). The melting temperatures of each are also recorded. Primers are purchased from 
Sigma-Aldrich unless noted otherwise. * denotes probes that were purchased from TIB® MolBiol 
(Adelphia, NJ).  
 
 
 
4.2 Preparation of LB­Ampicillin(Amp) Agar Plates  
 
This preparation is based off of a 1 Liter (L) mix. 15 g of Agar granulated (Difco™) and 25g of LB broth, 
Miller (Difco™) were measured. The agar and LB Broth were combined with 1L of double distilled H2O 
(ddH2O). The solution was mixed well and autoclaved (121.1°C). Solution was cooled to 55°C before 
adding 1 ml of 1000x Amp. The solution was aliquot into 20ml per each plate. This quantity prepared 
approximately 40 agar plates effective for up to three months. 
 
4.3 Preparation LB Broth, Miller  
 
This preparation is based off of a 0.5 Liter (L) mix. 12.5 g of LB broth was measure and combined with 0.5 
L of ddH2O. Solution was autoclaved and cooled to 55°C before used to inoculate bacteria plasmids. The 
solution was stored at room temperature or 4°C.  
 
4.4 Preparation of 2% Aagarose Gel 
 
The appropriate amount of Nusieve® 3:1 agarose (i.e. 2g for 100ml solution) was measured. This was 
combined with 1x TAE buffer in a flask. The flask was heated in a microwave for 2 mins. Solution was 
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cooled solution to 55°C by running heated flask under cold water. Then 4µl of 1% ethidium bromide was 
added before setting solution in gel cast. Agarose was set aside for at least 20 mins at room temperature 
before use.  
 
4.5 Gel Electrophoresis  
 
Electrophoresis was carried out at 100V along with 4µl of 100bp DNA ladder as a size marker. All samples 
contained 4µl of 10x loading dye buffer and the appropriate volume of sample per run. Gel was run until 
dye bands appeared descended halfway across the gel. Fragments were visualized by fluorescence under 
UV light (Alpha Innotech Corporation Multi-ImageLight Cabinet UV/Vis). The picture was captured if the 
PCR product was used for the subsequent experiments. The desired PCR product based on the DNA ladder 
were excised under the UV light (Fischer Scientific Transilluminator FBTIV-614) and further purified as 
described in the next section. 
 
4.6 QIAquick® Gel Extraction Kit Protocol (using a microcentrifuge) 
 
DNA sizes that were extracted ranged from 100 to 400bp in TAE buffer. QIAquick® kits (Valencia, CA) 
were stored in at room temperature (15-25°C). Kits last up to 12 months before showing any reduction of 
performance and quality.  The DNA band was excised from the agarose gel with a clean scalpel and 
combined with 750µl of Buffer QG in a 1.5 ml microcentrifuge tube. The sample tube was incubated at 
50°C for 10 mins in the Hybridizer Roller- Blotter (Techne, Ltd). After gel has completely dissolved, 350 
µl of isopropanol was added to the sample and mixed. Samples were placed in a QIAquick spin 
column/collection tube and centrifuged for 1 min at 13.2 runs per minute (RPM) (Spin column holds 
approximately 800 µl). Flow-through was discarded through a vacuum suction. The remaining sample 
solution was added to the spin column and centrifuged again. The flow-through was discarded again before 
adding an additional 500 µl of Buffer QG to the spin column (This step will remove all traces of agarose). 
Centrifuge was repeated and flow-through discarded. 750 µl of Buffer PE was added to the spin column 
and centrifuge for 1 min at 13.2 RPM. The flow-through was discarded and tube was centrifuged. 
19 
 
QIAquick spin column was placed in a clean 1.5ml microcentrifuge tube and 30 µl of Buffer EB was added 
to elute the DNA. The column was left standing for 1 min before final centrifugation. The eluted DNA 
samples of approximately 30 µl were stored in -20°C. 
 
4.7 Quantification of DNA (UltroSpec 2000/ Thermo Scientific NanoDropTM 
1000 Spectrophotometer) 
 
Concentration of DNA was determined by its absorbance at a wavelength of 260nm (OD260; UltroSpec 
2000 UV Visible Spectro) based on the following calculations: 2 µl of DNA sample was used in a ddH2O 
solution of 100 µl. The dilution factor of 50 was used to calculate the concentration of DNA in µg/µl. The 
formula used  
 
 
 NanoDrop™ instrument was also used for a more rapid approach of obtaining sample concentration. This 
machine also required 2 µl of DNA. The concentration is given in ng/µl. The copy number of the plasmid 
was calculated based on the sequence predicted molecular weight and Avogadro’s constant (6.0221415 × 
1023 mol-1).  
4.8 Preparation for DNA Sequencing Submission 
 
 GENEWIZ, Inc (www.genewiz.com) DNA sequencing company was used to submit and process 
DNA samples. The samples were prepared for DNA sequencing by calculating the DNA concentration (see 
Quantification of DNA), and then consulting www.genewiz.com to determine the appropriate DNA volume 
for submission. For plasmid samples of <6kb DNA size the DNA volume is approximately 8µl to produce 
around 400ng DNA. Adjustment of concentration was made accordingly by adding ddH2O. The primer 
volume is around 4µl for 8pmol. The total volume should be 12µl and stored in the 0.2ml 8-strip PCR tubes 
with sample labels on the side and top of the tubes. For purified PCR of DNA size between 200-500bp only 
3-10ng DNA should be submitted along with the same primer concentration listed above for a total volume 
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of 12µl. The analysis of gene sequencing result was performed on the multiple gene alignment server 
ClustalW http://www.ch.embnet.org/software/ClustalW.html  as well as on the software Chromas v2.3 to 
view the sequencing chromatographs. 
 
4.9 DNA Extraction and cloning methods 
 
4.9.1 DNA extraction 
 
Tumor tissue DNA was isolated by proteinase K/SDS treatment followed by phenol/chloroform extraction 
and ethanol precipitation.  The tumor tissues were from HBV-positive individuals as described previously 
[56].   
4.9.2 Polymerase Chain Reaction (PCR) 
 
The DNA of interest can be amplified by PCR reaction through repeated cycles of denaturation of template 
DNA, annealing between the single template strand to primers, and extension by the DNA polymerase. 
Adjustments to cycling conditions can be made according to experiment. A typical cycle includes 
denaturing at 94°C for 1 min, annealing for 30s usually 5-10°C below the lowest melting temperature of the 
two primers, and the extension step at 72°C at 1min per kb. 
 
4.9.2.1 PCR Direct Mutagenesis I Protocol 
 
This PCR was assembled in a reaction volume of 30µl containing 17.3µl of ddH2O, 3µl of 10x Buffer, 
2.4µl of dNTP, 1µl of HBV WT template, 0.3µl of PFU polymerase, and 3µl of 10µM 
HBVdmSeqFwd/HBVdmSeqRev and 3µl of 10 µM of the desired second primer of the specified mutation 
(i.e. 17624dm3 in 3’ direction in conjunction with HBVdmSeqFwd and 17624dm5 in the 5’ direction in 
conjunction with HBVdmSeqRev) in the3’ or 5’direction. Final primer concentration is 1µM. The 
amplification was carried out under the Eppendorf Mastercycler gradient at the following conditions: 94°C 
for 1mins, then 94°C for 30s, 52°C for 30s, 72°C for 30s for 34 cycles following elongation is extension at 
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72°C for 1min, and kept at 4°C until ready for gel electrophoresis analysis. PCR products were obtained 
under the gel extraction methods and used for subsequent PCR. 
Pfu polymerase presents optimal fidelity and yield. This polymerase contains an exonucleolytic activity that 
provides a low error rate and also creates blunt ends of DNA fragments that will help to facilitate cloning 
into PCR-Script® Amp (SK+) cloning vector.  
 
4.9.2.2 PCR Direct Mutagenesis II Protocol 
 
This PCR uses the PCR products of the previous PCR with overlapping templates in order to anneal and 
amplify the two primer-specific templates. The annealed 3’ end can extend and thus forms the double 
stranded DNA with the desired mutation[57]. This quantitative PCR was assemble in a reaction volume of 
24µl containing 12.3µl of ddH2O, 3µl 10x Buffer, 2.4µl of dNTP, 0.3µl PFU polymerase, 3µl of 
HBVdmSeqFwd, 3 µl of HBVdmSeqRev, and 2µl template 1 (PCR product with strand amplification in 5’ 
direction) and 3µl template 2 (PCR product with strand amplification in 3’ direction). Amplification was 
carried out under the Eppendorf Mastercycler gradient at the following conditions: 94°C for 1mins, then 
94°C for 30s, 52°C for 30s, 72°C for 30s for 34 cycles following extension at 72°C for 1min, and kept at 
4°C until ready for gel electrophoresis analysis. PCR products were obtained under the gel extraction 
methods (QIAquick® Gel Extraction Kit) according to the manufacturer’s specification and used in 
subsequent cloning steps.  
 
4.9.3 Ligation 
 
Stratagene’s PCR-Script® Amp Cloning Kit (La Jolla, Ca) was used for ligation and transformation steps.  
This cloning procedure requires an insert-to-vector ratio between 40:1 to 100:1.  The PCR-Script Amp 
SK(+) cloning vector contains an ampicillin resistant gene and promoter regions for T3 and T7 primers. 
And calculations were made based on quantification of DNA. The ligation reaction was prepared by adding 
the following components in order in a 1.5-ml microcentrifuge tube: 0.5 μl of the pPCR-Script Amp SK(+) 
cloning vector (10 ng/μl), 1 μl of PCR-Script 10× reaction buffer, 0.5 μl of 10 mM rATP, 2–4 μl of the 
blunt-ended PCR product or 4 μl of the control PCR insert, 1 μl of Srf I restriction enzyme (5 U/μl), 1 μl of 
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T4 DNA ligase (4U/μl), and distilled water (dH2Ofor a final volume of 10 μl. The ligation reaction was 
mixed gently and incubated for 1 hour at room temperature. Then the reaction was incubated for 10 
minutes at 65°C and then placed on ice until ready to perform the transformation into the XL10-Gold Kan 
ultracompetent cells. The negative control, the vector only, was included as one of the ligation reactions 
and transformation. 
 
 
Figure 8. pPCR-Script Amp SK (+) Vector Map. 
The vector contains the ampillicin resistance gene along with T7/T3 promoter regions. 
 
 
 
4.9.4 Transformation 
 
The sensitivity of competent cells should be considered when performing transformation such as ensuring 
that the cells are always placed on ice unless noted otherwise. Storage and handling should incorporate 
reduced exposure to temperature changes for optimal efficiency of cells. The XL10-Gold Kan 
ultracompetent cell, XL10-Gold β-mercaptoethanol, and a 1.5ml micro centrifuge tube were thawed/chilled 
on ice. The 20 μl of the cells were aliquot to a chilled1.5ml micro centrifuge tube on ice. The XL10-Gold 
β-mercaptoethanol mix of 0.8 μl was also added to the tube. The β-mercaptoethanol has been shown to 
increase transformation efficiency. The contents were gently mixed every 2 minutes and incubated on ice 
for 10 minutes. 2 μl of the cloning reaction (ligation) were then added and incubated for 30 mins on ice 
(note: Included pUC18 Plasmid as transformation control). The most critical step involved was the heat 
shock of the cell solution. The tube was placed in a 42°C water bath for 30 seconds. The duration of the 
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heat pulse is critical for obtaining the highest transformation efficiencies. (The heat shock process should 
be cautious as to not exceed 42°C). The tubes were immediately placed on ice for 2 mins. 200ul of 
preheated (42°C) S.O.C broth (Sigma-Aldrich® (St. Louis, MO)) were added to the tube and incubated at 
37°C for 40mins with shaking at 250 rpm. For color screening, the LB-Amp agar plates were prepared with 
20uM of IPTG and 4% X-gal 30 minutes prior to plating the transformations. 80ul of solution were plated 
per plate and plates were incubated overnight at 37°C. Colonies containing plasmids with inserts will 
remain white. The blue color can be enhanced by incubating the plates for two hours at 4°C following the 
overnight incubation at 37°C. Only white colonies were chosen for subsequent screening examination 
(colonies with a light blue appearance or colonies with a blue center were avoided). Note: Colonies 
containing inserts which were initially pure white may turn a light blue after ~2–5 days on the plate. 
 
4.9.5 Protocol for direct PCR screening for the clones that contain the 
insert DNA of interest 
 
Direct PCR screening of colonies isolated from the transformation plates was used to identify the clones 
that contain the insert DNA of interest. The total reaction volume of 28µl contains 18.3µl of PCR H2O, 3µl 
of 10xBuffer, 2.4µl of 2.5mM dNTP, 3µl of 10µM T3 primer and 3µl of 10µM T7, and 5U/µl of Taq 
polymerase. The clone is pipetted into the reaction by scrapping desired clone with pipette tip. The 
amplification was carried out under the Eppendorf Mastercycler gradient at the following conditions: 94°C 
for 10mins to activate the Taq polymerase, then 94°C for 30s, 52°C for30s, 72°C for 30s for 30 cycles 
following extension at 72°C for 4min, and kept at 4°C until ready for gel electrophoresis analysis.  If the 
colony screened contains the insert and vector, the gel analysis will display a strong band at the 
corresponding size. The desired colony can then be utilized for the subsequent miniprep. 
 
4.9.6 Plasmid DNA Purification Using QIAprep® Spin Miniprep Kit 
(Microcentrifuge) 
 
This miniprep kit was used for a fast and simple approach in purifying the desired plasmid DNA. The 
culture inoculation contained 4ml of LB broth, 4µl of ampicllin (0.1mg/ml), and the correct colony. The 
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solution is incubated and mixed overnight at 37°C. This culture will be used for the miniprep. First, the 
bacterial pellets were resuspended in 1.5ml microcentrifuge tube with 250µl of P1 buffer. Then 250µl of P2 
buffer were added and the tube was inverted 4-6 times. Then 350µl of N3 buffer was added and the tube 
was inverted 4-6 times. The sample solution was centrifuged at 13,000 RPM for 10 mins to remove cell 
debris. The supernatant was then loaded to the QIAprep spin column. Centrifuging the spin column will 
allow the supernatant to pass through the column and the DNA to bind and remain in the column. PE wash 
buffer was used to wash the column and then centrifuge. Before loading the elution buffer on the spin 
column, the column was centrifuged at 13,000 RPM to ensure the entire PE wash buffer was eluted. 
Transfer the column to a clean microcentrifuge tube and load 50 µl of elution buffer. The DNA is then 
eluted or stored for subsequent use at -20°C.   
 
4.10 Detection of HBV double mutation by PCR and direct sequencing 
 
A 186-bp DNA fragment from the position 1642 to 1827 of the HBV genome was amplified using the 
HBVdmSeqFwd (5’-ccc aag gtc tta cac aag agg-3’) and the HBVdmSeqRev (5’-gga aaa agt tgc atg gtg ct-
3’) primers (refer to Table 1).  The PCR reactions were assembled in a final volume of 25 μl containing 0.5 
U HotStart Taq (Qiagen®), 1X buffer, 200 μM of dNTPs, 1 μM of each primer, and 50 g DNA templates.  
The cycle profile was 95ºC for 10 min to activate Taq polymerase, followed by 95ºC 5 sec, 55ºC 15 sec, 
72ºC 10 sec for 40 cycles, and a final extension for 10 min at 72ºC.  The PCR products were then 
sequenced in both directions using the HBVdmSeqFwd and HBVdmSeqRev primers GENEWIZ, Inc DNA 
sequencing facilities. 
 
4.11 Detection of HBV double mutation by LNA clamp Real­time PCR 
 
The LNA-mediated clamped real time PCR reaction was assembled in a final volume of 10 µl containing 
1X reaction buffer, 0.5 unit of LightCycler® FastStart Taq polymerase (Roche Applied Science, 
Indianapolis, IN), 10µM HBVdmSeqFwd/HBVdmSeqRev, 50 ng of HCC tissue DNA as template, 0.4 μM 
of LCFwd and LCRev, 2.5 mM MgCl2, 500 ng/μl BSA, 200 μM dNTP, 0.2 μM Sensor, 0.2 μM Anchor, 
25 
 
and 2 µM HBV WT-specific LNA-containing oligonucleotide. The reaction was incubated in the 
LightCycler® II (Roche Applied Science) at 95ºC 10 min to activate the Taq polymerase, followed by 
amplification at 95ºC 5 sec, 65ºC 15 sec, 52ºC 10 sec, and 65ºC 10 sec for 45 cycles.  The LNA-
oligonucleotide has a predicted melting temperature (Tm) of 72ºC, roughly 12ºC higher than those of the 
PCR primers.  Both the Sensor and the LNA clamp are phosphorylated at the 3'-end so that they cannot 
function as primers.  The details of the oligonucleotides are in Table 1. Primer Sequences and the Tm of 
each olgionucleotides and Table 2. Probe Sequences and the Tm of each olgionucleotide. 
4.12 Melting Curve Analysis of PCR products 
 
Immediately after the amplification cycles, the PCR products were denatured at 95ºC and then cooled down 
to 40ºC to allow hybridization with the fluorescence-labeled probes.  The temperature was then increased 
from 40ºC to 68ºC at the speed of 0.1ºC/sec.  The dissociation of the WT sensor probe from the mutant 
HBV template is earlier (at a lower temperature) than from the WT HBV template due to the mismatch.  
Dissociation of the sensor probe terminates the fluorescence resonance energy transfer between the sensor 
and the anchor, which is recorded automatically by the instrument.  The results were analyzed using the 
LightCycler® software 3.5 (Roche Applied Science, Indianapolis, IN).   
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V. RESULTS 
 
5. 1 Construction of HBV double mutation standards 
 
In order to develop a PCR-based assay for the detection of the HBV double mutation as a potential DNA 
marker for the early detection of HBV associated HCC, various possible mutation controls for this assay 
setup were constructed. These sample constructs include positive controls with the DNA templates that 
contained the HBV double mutation DNA sequence 1762T/1764A, the 1762T mutation only, the 1764A 
mutation only, and the HBV wild-type. PCR directed mutagenesis technique was used to produce these 
mutated sequences. This technique involves a two step process utilizing specific primers involved in 
directing the sequencing designed on Vector NTI software (illustrated in Figure 9). In assembling the HBV 
double mutation, the first step is responsible for generating PCR products containing the mutation from the 
5’ and 3’ direction with primer pairs HBVdmSeqRev/17624dm5 and HBVdmSeqFwd/17624dm3 
respectively.  These primers are designated to carry the designated nucleotide mutations in the 5’ and 3’ 
direction. The PCR directed mutagenesis was performed to introduce the desired mutations in the 5’ and 3’ 
directions and was analyzed by agarose gel electrophoresis. These DNA products were created to contain 
overlapping sequences that can be used in the second set of the PCR direct mutagenesis protocol. The 
anticipated sizes are 132bp in the 3’ direction and 75bp in the 5’ direction (Figure 10). Below is the design 
outline for the sequencing primers and the subsequent gel electrophoresis of 1762T/1764A double mutation 
using the PCR direct mutagenesis I Protocol (Figure 9). 
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Figure 9.  PCR direct mutagenesis design.  
The 1700 region of the HBV DNA WT was used as template of the PCR. The primer pairs 
HBVdmSeqFwd/17624dm3 and HBVdmSeqRev/17624dm5 were used to generate the nucleotide mutation 
in the 3’ and 5’ direction respectively. A detailed sequence overlap of both anticipated DNA strands are is 
shown and the predicted  result of this design to produce two different double stranded DNA products is 
shown in Figure 10. 
 
 
 
 
 
 
 
Figure 10. Predicted DNA sequence results generated by PCR directed mutagenesis I protocol 
These are the two desired DNA products. They contain overlapping sequencings containing the double 
mutation. These primer specific templates are used to form the double stranded DNA containing the HBV 
double mutation. Their respective band sizes are also listed.  
 
 
 
The results of the two PCR products are shown in the following gel electrophoresis (Figure 11). The 
calculated size for 17624dm5 band product is 75bp and band produced is below the first band in the 100bp 
ladder. This size can be approximated to be correct. The calculated size for 17624dm3 band product is 
132bp and the band produced is marked about 1/3 above the 1st band (size of 100bp) of the ladder and 
below the 2nd band (size of 200bp). This size also can be approximated to be correct. These two bands were 
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excised and purified using the QIAquick® Gel Extraction Kit (Valencia, CA). Once purified, these 3’ and 
5’ DNA fragments containing the mutation were used as DNA templates for the second step of PCR direct 
mutagenesis following the PCR Directed Mutagenesis II Protocol.  
 
 
 
 
Figure 11. HBV 1762T/1764A Double Mutation PCR directed mutagenesis I Results 
The PCR directed mutagenesis I protocol was used to construct the 5’ and 3’ direction strand for the 
1762T/1764A double mutation. The primers that were used were HBVdmSeqRev and 17624dm5 in the first 
band labeled 17624dm5. The HBVdmSeqFwd with 17624dm3 primers were used in the second band 
labeled 17624dm3. 100bp DNA ladder (New England Biolabs, Inc (Ipswich, MA)) was used to confirm the 
size of bands.  
 
 
 
 
The second step of PCR directed mutagenesis is responsible for joining the 3’ and 5’ DNA fragments that 
contain the overlapping sequence. Figure 12 entails the design and primer outline. The second step of the 
PCR directed mutagenesis II protocol was performed and the PCR products were analyzed in the same 
fashion.  
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Figure 12. Schematic diagram of the second PCR reaction of the PCR directed mutagenesis 
The two PCR products from the previous cloning PCR were both used as templates and combined into o
reaction mix. The primers HBVdmSeqFwd and HBVdmSeqRev were also used in the reaction
row represents the direction of the HBVdmSeqFwd primer and the bottom row represents the 
HBVdmSeqRev primer direction. The templates provide a primer-specific template that allows for 
ne 
. The top 
nnealed 5’ and 3’ end to extend forming the double stranded DNA containing the double mutation.  
The expected double strand DNA product is listed below (Figure 13). The gel electrophoresis displayed a 
band size below the 200bp ladder mark and is approximated to be the similar in size as the expected size of 
186bp (see gel picture in   Figure 14). Once excised and purified, the DNA fragment can be used in 
Stratagene’s PCR-Script® Amp Cloning Kit in order to produce the clones of choice. 
 
a
 
 
 
 
 
 
Figure 13. Predicted DNA sequence results generated by PCR directed mutagenesis II protocol 
This is the anticipated DNA product that contains the double mutation using the HBV 1700WT as the PCR 
mplate. The respective band size is also listed.  
 
 
te
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Figure 14. HBV 1762T/1764A Double Mutation PCR directed mutagenesis II Results 
The purified DNA fragments from bands 17624dm5 and 17624dm3 in the previous gel (Figure 11) were 
both used as templates in the second step of the PCR directed mutagenesis with primers HBVdmSeqFwd 
and HBVdmSeqRev. This formed the band labeled Combo17624. The calculated size should account fo
the overlapping region form the two previous bands and the correct size is around 187bp. 100bp DNA
ladder (New England Biolabs, Inc (Ipswich, MA) ) was used to confirm the size of bands. The band 
adjacent to the 2nd band (200bp) from the bottom and is approximated to be the same size. This band
r 
 
 was 
xcised and the PCR product was purified. This was used as the DNA template in the ligation step.  
The first step involved in the Stratagene’s PCR-Script® Amp Cloning Kit is the ligation step. This utilizes 
a precut pPCR-Script Amp SK(+) vector (Figure 8 ). The DNA fragment is cloned into the vector using this 
kit. Srf I restriction enzyme was used to cut open the vector (Figure 15) and T4 ligase was also used to 
insert and attach the insert DNA from the PCR products into the vector. The simultaneous opposite 
reactions of Srf I restriction enzyme and T4 ligase is used according to Stratagene Kit protocol in order to  
increase the efficiency of the blunt-ended DNA fragment ligation ( see Figure 15).  
e
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Figure 15. Diagram of pPCR-Script AMP SK(+) Vector 
This vector was used to insert DNA sequence. The red box denotes the site of the Srf I enzyme cut and the 
T7/T3 promoter regions are also noted here to display the priming sites necessary for the Transformation 
screening PCR. 
Transformation was performed following the protocols mentioned. The transformation was then plated onto 
LB-Amp agar plates and incubated overnight. The plates were observed and colonies that were distinctly 
white underwent the PCR screening. In this particular cloning kit, the pPCR-script vector contains 
promoter regions for T3 and T7 primers (Figure 15). This enabled the clones to be identified through the 
PCR reaction using T3/T7 primers. The expected size is around 400bp and that includes the vector and the 
insert DNA. The gel electrophoresis results in Figure 16 showed one positive colony with a distinct band 
around 400bp. Figure 16 displays one run of the PCR screening protocol and delineates the occurrence of 
false positives. 
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Figure 16. PCR screening of the transformant  
With a vector size that is approximately 172bp and with the insert size of 186bp, the clone that displays a 
band size around 358bp would correctly contain both vector and insert. Sample 12 is the only sample that
displays a positive colony while sample 8, 10, 13 show sizes around 200bp. These samples would only 
include the vector without the inse
 
rt DNA. The other samples that display no bands were white colonies 
at were ruled as false positives. 
The positive colonies were then inoculated and incubated overnight in LB broth. Miniprep was performed 
in order to isolate and purify the DNA. This end product was submitted for DNA sequencing at GENEWIZ, 
Inc to verify the correct sequence. This procedure was used to generate the plasmids constructs containing 
the HBV 1762T mutation, 1764A mutation, and the HBV wild-type (WT). All DNA sequence results were 
verified through GENEWIZ direct sequencing and were analyzed through the DNA multiple alignment tool 
on the ClustalW server (Figure 17).  Thus, the plasmids containing the desired HBV mutations were 
successfully constructed and were used as DNA templates to develop and evaluate the real time PCR 
assays for the detection of the HBV double mutation. 
th
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HBVadw+1700WT            CCAAGGTCTTACACAAGAGGACTCTTGGACTCCCAGC 
HBV_Double_Mutation      CCAAGGTCTTACACAAGAGGACTCTTGGACTCCCAGC 
HBV_dM_1764A             CCAAGGTCTTACACAAGAGGACTCTTGGACTCCCAGC 
HBV_dM_1762T             CCAAGGTCTTACACAAGAGGACTCTTGGACTCCCAGC 
                         ************************************* 
 
HBVadw+1700WT            AATGTCAACGACCGACCTTGAGGCCTACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGA 
HBV_Double_Mutation      AATGTCAACGACCGACCTTGAGGCCTACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGA 
HBV_dM_1764A             AATGTCAACGACCGACCTTGAGGCCTACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGA 
HBV_dM_1762T             AATGTCAACGACCGACCTTGAGGCCTACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGA 
                         ************************************************************ 
 
HBVadw+1700WT            GCTGGGGGAGGAGATTAGGTTAAAGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGT 
HBV_Double_Mutation      GCTGGGGGAGGAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGT 
HBV_dM_1764A             GCTGGGGGAGGAGATTAGGTTAAAGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGT 
HBV_dM_1762T             GCTGGGGGAGGAGATTAGGTTAATGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGT 
                         *********************** * ********************************** 
 
utation for the double mutation sequence, the 1762T only mutation, and the 1764A only mutation. 
           
 
HBVadw+1700WT            CTGCGCACCAGCACCATGCAACTTT 
HBV_Double_Mutation      CTGCGCACCAGCACCATGCAACTTT 
HBV_dM_1764A             CTGCGCACCAGCACCATGCAACTTT 
HBV_dM_1762T             CTGCGCACCAGCACCATGCAACTTT 
                         *************************                                    
Figure 17. DNA Sequencing results for HBV standards. 
DNA sequencing results were confirmed with GENEWIZ, Inc. Multiple alignment was performed on
ClustalW server for the three controls and the wild type template. The alignment showed the correct 
m
 
 
 
 
 
 
 
                                   1741       1751      1761       1771     1781       1791      1801 
                                         |                    |                  |                  |                  |                    |                  |     
HBVadw+1700WT      GCTGGGGGAGGAGATTAGGTTAAAGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAGCACCAT 
************************************************* HBV_dM             ***********************T*A**
HBV_dM_1764A       *************************A*************************************************** 
he PCR cloning technique. This double 
utation is represented correctly as well as the 1764A and 1762T.  
HBV_dM_1762T       ***********************T***************************************************** 
Figure 18. Control Standard DNA Alignment. 
his alignment shows the mutation that was produced as a result of tT
m
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In current studies involving gene therapy and expression, the use of LNA has demonstrated the positive 
effects in improving and monitoring gene delivery[54]. This could be a potential use in assay development 
for increasing detection sensitivity and specificity. LNA is an analogue of DNA where the ribose ring is 
constrained by a methylene linkage and in essence locked. This provides the advantage of increased 
binding affinity, sequence specificity, and high melting temperatures due to LNA’s conformation 
restriction (see Figure 7 for more details). To develop this PCR-based assay, LNA was used to explore and 
observe the effects on the detection outcome.  
 
 
 
5.2 Establishment of LNA­mediated clamped PCR assay for the detectio
of the HBV 1762T/1764A double mutation 
 
Figure 19. Design of Oligonucleotides Used. 
BV wild type (WT) DNA sequence (see Figure 2) from positions 1631 to 1830 is displayed. The position 
nd the direction of the olgionucleotides are shown with line arrows aligned to the HBV WT sequence. The 
 
H
a
sequence of the LNA-containing oligonucleotide is listed with the LNA monomers in upper-case letters. 
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gCl2, 500 ng/μl BSA, 200 μM dNTP, 0.2 μM Sensor, and 0.2 μM Anchor. The reaction was incubated in 
2T/1764A: 
BV WT gave a Tm around 59.5ºC. The mutation HBV 1764A gave a Tm around 61.5 ºC 
nd HBV 1762T gave a Tm around 60 ºC which are very similar to the HBV WT Tm. These melting points 
ere noted for their Tm differences, where HBV 1762T/1764A and HBV WT showed a difference ~4 ºC 
hile the HBV 1764A and HBV 1762T showed a greater Tm difference from the Tm of HBV 
762T/1764A. 
 
 
 
 
The standards were used to develop the assay in a real-time PCR-based assay on the Roche LightCycler® 
2.0.  A 0.1pg of DNA template was used for assay development.  The PCR reactions were performed as 
described in Section 4.11. The real time PCR reaction was assembled in a final volume of 10 µl containing 
1X reaction buffer, 0.5 unit of LightCycler® FastStart Taq polymerase (Roche Applied Science, 
Indianapolis, IN), 50 ng of H DNA as template, 0.4 μM of HBVdmLC Fwd and HBVdmLCRev, 2.5 mM 
M
the LightCycler® II (Roche Applied Science) at 95ºC 10 min to activate the Taq polymerase, followed by 
amplification at 95ºC 5 sec, 65ºC 15 sec, 52ºC 10 sec, and 65ºC 10 sec for 45 cycles.  At the end of the 
PCR reaction, the melting curve analysis was performed to characterize the products as shown in Figure 20. 
 
The HBV 1762T/1764A showed a melting curve which peaks around 56ºC (Figure 20; HBV 176
line 1) and the H
a
w
w
1
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Figure 20. Differentiation of Standard Clones by melting curve analysis. 
elting curves of (1) HBV 1762T/1764A (2) WT HBV (3) HBV 1764A (4) HBV 1762T and (5) H2O.  
T A
 
T A r 
T A
T A line 
nce 
T HBV and mutant DNA 
owed the Tm peak occurring around the WT HBV (60ºC) disappeared, while the mutation-specific Tm 
eak was preserved (Figure 21; Equal molar mix plus LNA clamp:line 7).   
M
 
 
 
 
To determine the sensitivity and specificity when the real-time PCR is faced with a sample that contains a 
mix of HBV 1762 /1764  and HBV WT, the assay was tested with and without the HBV WT-specific 
LNA-containing clamp described in the Methods 4.1 Primers/Oligonucleotide Preparation section. In the
absence of LNA, the HBV WT DNA control showed a melting curve which peaks at around 59.5ºC (Figure 
21;WT HBV (300 copies):line 2) and the HBV double mutation control gave a Tm peak at around 55ºC 
(Figure 21; HBV 1762 /1764  (300 copies):line 1).  These two Tm difference (~4 ºC) approximated simila
results as Figure 20. The control HBV 1762 /1764  and HBV WT samples in the presence of LNA clamp 
showed Tm around 56 ºC and 60 ºC respectively (Figure 21; HBV1762 /1764 :line 4 and HBV WT :
5).  When the WT HBV and the mutant DNA were mixed at approximately equal molar ratio in the abse
of LNA, a broad Tm peak spanning between 56 ºC  and 60ºC was observed (Figure 21; Equal molar 
mix:line 6). In the presence of LNA clamp, the equal molar mix sample of W
sh
p
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Figure 21. Differentiation of the HBV 1762T/1764A double mutation from the WT by melting curve 
analysis and the WT clamp. 
elting curves of (1) HBV 1762T/1764A (300 copiesM ); (2) WT HBV (300 copies); (3) H2O only; (4) HBV 
762T/1764A plus LNA clamp (5) HBV WT plus LNA clamp; (6) WT:HBV 1762T/1764A equal molar mix; 
) WT:HBV 1762T/1764A mix plus LNA clamp.   
 
Also, in the presence of LNA clamp, the HBV WT only sample showed a lower Tm peak compared to the 
HBV WT sample in the absence of the LNA clamp (Figure 21; HBV WT plus LNA clamp :line 5). 
Through the amplification curve in Figure 22, the differences between line 3(WT HBV (300 copies)) and 
line 4 (WT HBV (300 copies) plus LNA clamp) evidences this suppression. Also. The suppression of the 
HBV double mutation seem to be minimally effected by the presence of the LNA clamp (Figure 22;  HBV 
1762 /1764  (300 copies): line 1 and HBV 1762 /1764  (300 copies) with LNA clamp:line 2). The results 
of the melting curves and the amplification curves indicate that the LNA-containing clamp has specifically 
suppressed the WT HBV signal, and further has minimal suppression if any to the detection of the HBV 
762T/1764A mutation in the presence of HBV WT.  
1
(7
 
 
T A T A
1
 
 
 
 
38 
 
 
 
 
 
Figure 22. Amplification curves for HBV 1762T/1764A double mutation and
T A T
 HBV WT samples 
Amplification curves of (1) HBV 1762 /1764  (300 copies); (2) HBV 1762 /1764A (300 copies) with LNA 
clamp; (3) WT HBV (300 copies); (4) WT HBV (300 copies) plus LNA clamp; (5) HBV 1762T/1764A 
equal mo r mix (6) WT:HBV 1762T/1764A equal molar mix plus LNA clamp; 
 
To observe how efficiently the LNA-oligonucleotide clamp performs, increasing amounts of HBV 
1762 /1764  plasmid samples were mixed with a consistent 30,000 copies of WT HBV plasmid. This was 
then used as the PCR templates. The copy number of each sample was calculated based on molecular 
weight and Avogadro’s number. The amplification of 30,000 copies of HBV WT was suppressed in the 
presence of the 2 µM LNA clamp (Figure 23; line 3).  Also in the presence of the 2 µM LNA clamp, not 
only were 30,000 copies of HBV WT suppressed during the amplification, but also 10 copies of the HBV 
1762 /1764  double mutation  was detected in the 1:3,000 mutant/WT ratio (Figure 23; line 5). The 
detection of such low levels of mutant DNA was not affected by the presence of the 2 µM LNA clamp 
(Figure 23; 10 copies of HBV 1762 /1764  plus LNA clamp:line 1 and 10 copies of HBV 1762 /1764
:line 6). At lower mutant/WT ratios, the double mutation was not detectable possibly due to primer titration 
by the excessive WT HBV (Figure 25; line 4). Thus, the detection sensitivity is at a mutant/WT ratio of 
:3,000 in the presence of the LNA clamp. 
la
 
 
T A
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T A T A 
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Figure 23. Sensitivity of LNA-mediated clamped real-time PCR for detection of HBV 1762T/1764A 
double mutation 
Melting curves of (1) 10 copies of HBV T/1764A plus LNA clamp; (2) 30,000 copies of WT HBV; (3)
30,000 c ies of WT HBV plus LNA cl
1762  
amp; (4) 10 copies of HBV 1762T/1764A plus 30,000 copies of WT 
HBV; (5  copies of HBV 1762T/1764A plus 30,000 copies of WT HBV plus LNA clamp; (6) 10 copies 
of HBV 1762T/1764A; (7) H2O only.  
 
To determine the minimal copy number of the HBV 1762 /1764  plasmid that is detectable by the LNA-
clamp PCR assay, varying amounts of the HBV 1762 /1764  plasmid were used per reaction with the WT 
HBV DNA constant at 30,000 copies.  The amplification curves showed a consistent detection of 10 copies 
of the m t HBV DNA (Figure 24; 10 copies HBV 1762T/1764A: line 4). 
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Figure 24. Amplification curves of HBV 1762 /1764  double mutation. 
1) 3,000 copies; (2) 300 copies; (3) 30 copies; (4) 10 copies; (5) 5 copies; (6) H2O only.  The PCR was 
arried out in the presence of 30,000 copies of WT HBV DNA and 2 µM WT clamp.  
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5.3  Detection of the HBV 1762T/1764A double mutation from HCC 
samples by the LNA­mediated clamped PCR assay 
 
To see the accuracy of the LNA-clamp PCR, DNAs extracted from HCC tumor samples were tested. The 
samples were run through a HBV detection of PCR with and without the LNA-clamp (See Section 4.10 
Detection of HBV double mutation by PCR and direct sequencing). The PCR products were amplified by 
the primers HBVdmSeqFwd/HBVdmSeqRev and further analyzed by DNA sequencing. The results of the 
HCC tumor samples in the absence of LNA are highlighted in the figure below (Figure 25).  
 
 
 
 
Figure 25. HCC Tumor DNA sequencing alignment without LNA. 
The wild type (WT) is from GeneBank Accession #X04615.  Bases identical to the WT sequence are 
indicated by the colon signs.  N indicates a base that cannot be determined automatically by the software.  
Sample F is the only sample to show a mixture of bases which suggest a mixture of the mutant and WT.. 
While sample A displays a clear cut double mutation sequence.  
 
 
 
 
Out of six HCC DNA samples, the direct DNA sequencing results showed that all samples but samples A 
and F showed to only contain the WT sequences at the region examined. Interestingly, samples A contained 
not only 1762T/1764A double mutation, but an additional mutation at the location 1752 (A-G) was 
identified.  Sample F was shown to be a mixture of WT and mutations.  
 
The six HCC DNA samples were then tested with the LNA-mediated PCR clamping and underwent post-
PCR melting curve analysis.  Sample A, the only sample which showed distinct double mutation by direct 
sequencing, displayed a melting curve with a lower Tm than that of the double mutation (Figure 26).  This 
may have occurred due to the additional mutation (A to G) at 1752.  Sample F, which showed mixed bases 
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at 1762 and 1764 indicated by the DNA sequencing, produced a typical profile of a double mutation in the 
presence of LNA clamp (Figure 26; line F). This result of the HBV double mutation Tm in the presence of 
LNA clamp would have been suppressing the WT signal and enhancing the underlying double mutation 
signal.  This matches the conditions described in Figure 21 (WT:HBV 1762T/1764A equal molar mix:lines 6 
and WT:HBV 1762T/1764A mix plus LNA clamp:line 7) using mixed plasmids.  Interestingly, samples D 
and E, which displayed WT by the direct DNA sequencing, gave a typical Tm profile of the 1762T/1764A 
double mutation in the presence of the LNA-clamp.  The remaining two samples, B and C, presented a WT  
profile in the absence of the LNA clamp and matched the direct DNA sequencing results. 
 
 
 
 
Figure 26. Analysis of HCC tumor DNA by LNA-mediated clamped real-time PCR and of melting 
curves. 
The melting curves for the 6 HCC tissue samples are shown here. Reactions from samples B and C did not 
have the LNA clamp and display a HBV WT profile. Samples A displays a clear mutation profile but does 
not match the HBV double mutation profile that is shown by samples E, D and F.  
 
 
 
Due to the inconsistency shown by samples D and E between real time PCR and direct DNA sequencing, a 
subsequent PCR was run with samples D, E, and F with and without the LNA clamp and analyzed through 
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direct DNA sequencing. The sequences below display the inconsistencies that could have occurred between 
the sequencing without the LNA clamp and the real time PCR melting curve analysis with the LNA clamp. 
 
 
 
 
Figure 27. DNA Sequence Alignment of HCC samples with and without LNA 
The samples that displayed inconsistency were run on a simultaneous PCR with and without the LNA-
clamp. HBVdmSeqFwd and HBVdmSeqRev primers were used for amplification. They were then sent for 
sequencing.  
 
 
 
 The chromatogram sequencing files for the samples D, E and F are shown below (Figure 28).  In sample D 
and E without LNA, 1762A and 1764G are the dominant bases, but 1762T and 1764A are also represented 
in the chromatogram in smaller amounts (Figure 28; left panel).  In sample F without LNA both bases at 
1762 and 1764 showed mixed amounts (Figure 28; left panel). The PCR was performed on the three 
samples in the presence of the LNA clamp as well. The chromatographs confirmed the presence of HBV 
double mutation in the samples D and E as well as exposing the presence of the HBV double mutation in 
sample F (Figure 28; right panel). Further, they demonstrated that the clamp that suppresses the 
amplification of the WT HBV DNA can increase the sensitivity of DNA sequencing. In conclusion, the 
LNA clamp mediated PCR assay was shown to be more sensitive than the direct DNA sequencing method 
for the detection of HBV double mutation. The addition of LNA clamp in the PCR reaction for DNA 
sequencing can enhance the sensitivity to detect the mutations by DNA sequencing. 
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Figure 28. Effect of LNA-mediated PCR clamping on DNA sequencing. 
Regular PCRs were performed for reactions with and without the LNA-containing WT HBV clamp (+ or - 
LNA clamp) and were subjected to direct sequencing.  The chromatogram files are shown.  
TTAAAGGTCTT is the WT sequence with 1762A and 1764G underlined.  TTAATGATCTT contains 
1762T and 1764A double mutation.  Note that 1762 and 1764 positions contain mixed bases.  In panel D E 
and F  on the left side only sample F shows a mixture sequence of the HBV WT sequence and HBV double 
mutation sequence. However, on the left side all panels display the HBV double mutation sequence.  
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5.4  Sensitivity of real­time PCR assay detecting HBV 1762T/1764A 
double mutation 
 
To further investigate the extent of WT suppression and sensitivity of the clamp in DNA sequencing 
mixtures, mixtures of the double mutation and WT plasmids were ran as templates (0.1pg/µl) in PCRs in 
the presence or absence of the clamp (See 4.10 Detection of HBV double mutation by PCR and direct 
sequencing). The ratios of double mutation (DM) plasmid to WT plasmid 1:4, 1:8, and 1:16 with and 
without the clamp were tested. The amplicons were purified and sent for direct DNA sequencing. The DNA 
sequencing text output showed that in the presence of the LNA-clamp, the HBV double mutation was 
detectable only in the 1:4 ratio and could no longer be detected in the presence of increasing HBV WT 
(Figure 29).  
 
 
 
 
Figure 29. DNA Sequence Alignment of DM:WT dilution samples 
Samples containing increasing amounts of WT were tested in the presence of LNA and sent for direct DNA 
sequencing 
 
 
 
 
However, the chromatographs of the DM: WT ratio sample without the clamp showed that there is a 
presence of the double mutation, moreover in the reaction in the presence of the LNA clamp, the double 
mutation is exposed. In the samples of 1:8 and 1:16 ratio in the absence of the clamp the direct DNA 
sequencing results depict WT sequences. When looking at the chromatographs, the activity of the LNA 
clamp can be highlighted as the presence of the HBV double mutation is more visible in the 1:8 and 1:16 
ratio samples without the LNA clamp. In the presence of the clamp, this HBV WT suppression activity is 
noted in the 1:8 and 1:16 ratios of the DM: WT sample. The chromatographs facilitate understanding of the 
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extent of the LNA-clamp suppression activity in the DNA sequencing and thus detecting the HBV double 
mutation. 
 
 
 
 
Figure 30. Effect of LNA-mediated clamping on samples containing mixtures. 
The chromatographs display the DNA sequencing results of the PCR reactions for the DM:WT plasmid 
samples.  
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5.5  Assessment of potential False Positives 
 
The LNA-Clamp showed it was able to suppress the WT in the amplicon region (Figure 30) and distinguish 
between a sample that contained the double mutation 1762T/1764A or further mutations. However, the 
region complementary to the LNA clamp could present mutations. This possible polymorphism was tested 
here. First a NCBI Blast was performed in the HBV database against the sensor sequence.  The mutations 
along this sequence are shown below with their varying frequencies. In order to investigate the possible 
polymorphism region the LNA clamp area was shaded in gray.  This evidenced only one possibility based 
on this database search that can create false positive results when the LNA clamp cannot properly bind the 
WT. This mismatch at 1757G Æ A could escape the suppression by the LNA clamp and is investigated in 
this section. 
 
 
 
                            1751      1761     1771 
                                   |                       |                       | 
Clamp              GGttAaAGGTcTTtGt 
WT       GAGATTAGGTTAAAGGTCTTTGTACTAGG  
pattern 1   ……………………………………………………………T…………    22%  
pattern 2  ……………………………………………………………………………    18%  
pattern 3  …………………………………T…A…………………………………    15%  
pattern 4  ……………………A……………………………………………………    8%  
pattern 5    …………C……………………………………………………………    6%  
pattern 6   ……G…………………………………………………………………    4%  
pattern 7   …………………………………………………………………G……    3% 
 
Figure 31. BLAST analysis of HBV sequences. 
The sensor sequence was the “input sequence” under observation. A total of 3501 sequences were collected 
and the most frequent sequences are listed. The LNA clamp sequence is highlighted as the target region for 
polymorphisms (capitalized letters are LNA monomers).  
 
 
 
 
A 1757A mutation plasmid was constructed in the same procedures described in section 5.1. The direct 
DNA sequence alignment can verify the DNA fragment in Figure 32. The plasmid also contained a 
mutation 1772CÆT. This mutation however lies outside of the LNA clamp region and was not predicted to 
have an effect in the binding upon the WT. 
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Figure 32. Plasmid 1757 A mutation DNA Sequence Alignment. 
The DNA sequence of the plasmid 1757 clone shows a desired mutation at position 1757 and an undesired 
mutation at position 1772. 
 
 
 
Real-time PCR was run with the plasmid 1757A mutation. In the absence of LNA clamp, the HBV 1757A 
mutation displayed a shift in the Tm (55.5°C), but it is also differentiated from the double mutation Tm 
(57°C). This shows that the distinction of the mutations does not yield the same Tm and thus the double 
mutation can still be differentiated through the melting curve analysis (Figure 33; HBV 1757A: line 1 and 
HBV 1762T/1764A double mutation: line 2).  
 
 
 
 
Figure 33. Melting Curve Analysis of HBV 1757A mutation without the LNA clamp. 
The DNA template concentration used for all samples was 0.1pg. 1)HBV 1757A 2) HBV 1762T/1764A 
double mutation 3) HBV WT 4) H2O 
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Also, a real-time PCR was tested in the presence of the LNA-clamp. The HBV 1757A mutation did not 
shift the Tm in the presence of the clamp (Figure 34: line 1). The suppression of the HBV 1757A mutation 
can be described in the amplification curve (Figure 35; HBV 1757A with clamp: line 4). The LNA clamp 
also displayed an inhibition of the HBV WT (Figure 35; HBV WT with clamp: line 2). The inhibition 
however was less pronounced in the HBV 1757A most likely due to the mutation along the LNA clamp 
region. 
 
 
 
 
Figure 34. Melting Curve Analysis of HBV 1757A mutation with the LNA Clamp. 
The DNA template concentration used for all samples was 0.1pg and the LNA clamp concentration used 
was 2µM. This RT-PCR ran for 55 cycles. (1) HBV 1757A (2) HBV 1762T/1764A double mutation (3) 
HBV WT 
 
 
 
Also, the HBV 1762T/1764A double mutation was not significantly affected by the WT-specific LNA 
clamp. Figure 35 displays the amplification of samples with and without the LNA clamp and shows the 
inhibition that occurs due to the LNA-clamp. HBV 1757A is inhibited (Figure 35; without LNA line 3 and 
with LNA line 4) but not as significantly as HBV WT (Figure 35; line 1 and line 2). Furthermore HBV 
1762T/1764A double mutation is hardly effected by the LNA-clamp (Figure 35; HBV 1762T/1764A: line 5 
and HBV 1762T/1764A with the LNA clamp:line 6).  
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Figure 35. Amplification Curve of HBV 1757A mutation. 
(1) HBV WT without the clamp (2) HBV WT with clamp ( 3) HBV 1757A without the clamp (4)HBV 
1757A with the clamp (5) HBV 1762T/1764A double mutation without the clamp( 6) HBV 1762T/1764A 
double mutation with the clamp 
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VI. DISCUSSION 
 
 
The goal of this experimental design was to develop a sensitive assay to detect HBV 1762T/1764 double 
mutation in patient body fluids such as blood or urine for the ultimate purpose of having a noninvasive test 
for the early detection of HCC. The LNA mediated clamp real-time PCR assay using hybridization probe 
was successfully developed with the assay sensitivity of 10 copies in the presence of 30, 0000 copies of 
wild-type background. This has demonstrated to be more sensitive and rapid than the current available 
assay with a sensitivity of 1:20 of the mutant to wild type ratio[31].  
 
Before beginning assay development PCR directed mutagenesis techniques were used to produce standard 
clones with the DNA sequences containing the HBV WT and HBV 1762T/1764A. These clones were 
confirmed by direct DNA sequencing (Figure 17) and used as standards in the subsequent real-time PCR 
assay development to be able to differentiate the samples as well as account for assay run-to-run variability. 
The use of hybridization probes in a PCR based assay was to overcome the current labor intensive post 
PCR manipulation techniques.  Hybridization probes provide the advantage of post PCR melting curve 
analysis capability. The probes consisted of an LCRed640-labeled Anchor oligonucleotide, and a 
fluorescein-labeled Sensor oligonucleotide that is complementary to the HBV WT sequence (Figure 19). 
Fluorescence resonance energy transfer (FRET) between the LCRed640 and fluorescein occurs when the 
two probes anneal to the same template during the PCR cycling. During the melting curve analysis where 
PCR products were denatured at 95°C and then cooled to 40°C, the slow temperature increase of 
approximately 0.1°C/s causes the Sensor probes to gradually dissociate from the template resulting in loss 
of the FRET signal.  
 
In this assay, standard clones of the HBV double mutation and HBV WT were tested and the WT displayed 
a melting curve peak at about 59°C while the double mutation displayed a melting curve peak at about 
55°C (Figure 20). This is the evidence that there is a difference in the melting curve peaks due to the 
mismatch between the Sensor and the double mutation template. This mismatch causes the Sensor to 
dissociate earlier during the melting curve analysis, thus the shift in Tm of the double mutation from the 
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WT. It is important to note repeated assays of these standards, Tm peaks displayed slight shifts. This could 
be due to variations from experimental runs such as salt concentrations. The difference in Tm peaks 
between the WT and HBV double mutation however remained consistent (~4°C). Thus, plasmid standards 
were included in each experimental run for comparison purposes. Real  time PCR using similar 
hybridization probes for detecting HBV 1762T/1764A have also been reported by Zhang et al[31]. They also 
showed a similar Tm difference between the WT and the double mutation, however the sensitivity of the 
assay is only about 1:20 mutant/WT ratio.  
 
In this design, LNA-containing oligonucleotide was used to increase the sensitivity. LNA is a novel class of 
bicyclic DNA analogs that have exceptionally high affinity and specificity toward their complementary 
DNA target molecules [52, 54, 58]. The LNA-containing oligonucleotide was designed to have a higher 
Tm than the amplification primers. During the PCR cycling, the LNA oligonucleotides anneal to the WT 
template before the PCR primers and stay annealed during the 65°C synthesis step. This in effect blocks the 
polymerase extension on the WT DNA template and suppresses the HBV WT amplification (Figure 28).   
 
In an additional study of LNA-mediated effects of varying ratios of mutant/WT, the LNA can still be seen 
to exhibit suppression of the WT in a ratio of up to 1:16 mutant/WT (Figure 30).  The clamp shows 
competition with the Sensor in the real time PCR thereby diminishing the WT signals. This enables a 
highly sensitive detection of the double mutation even in the presence of 3,000 fold excess of HBV WT 
(1:3,000 mutant/WT ratio). In the absence of the LNA-clamp, the sensitivity decreases to a ratio of 1:4  
(Mutant: WT). The intensity of the FRET signal depends on the optimal probe/template ratio.  Too much 
templates (as a result of over amplification) can cause the Sensors and Anchors to bind to separate 
templates, resulting in reduced FRET signal.  Therefore the intensity of the FRET signals in the melting 
curve is not used for quantification purpose but is used for mismatch detection only.   
 
An obstacle in detecting the HBV 1762T/1764A double mutation is the variable region it is located in. 
Because of the HBV virus replicates its DNA genome using a reverse transcriptase that produces high error 
rate, many mutations can be found along the double mutation region[44]. The polymorphic mutation(s) can 
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affect and impact the assay mechanism in various ways. This can be seen when there are significant 
variations along the amplification primer regions causing the PCR amplification to be compromised thus 
invalidating any potential detection of the double mutation. This can be remedied by placing the 3’ end of 
both primers (HBVdmSeqFwd/HBVdmSeqRev) at highly conserved regions of the HBV genome.  Also, 
when the double mutation containing template is accompanied by additional mutations in the region 
covered by the sensor probe, the Tm will incur an additional shift from that Tm of the double mutation. 
This shift deviation from the double mutation occurred in sample A (Figure 26). This occurrence of an 
atypical melting curve would require DNA sequencing to clarify. Lastly, certain mutations or variants in 
this particular region may escape the inhibitory effect of the clamp. A NCBI BLAST was performed to 
search for the known variant in the LNA clamp region. There is only one variant at position 1757 where an 
A mutation occurs  in the Sensor region in addition to the 1762T/1764A mutation that accounted more than 
1% of the total hits in the entire search (Figure 31). A 1757A plasmid was constructed in the same fashion 
as the WT and double mutation plasmids and tested under the same LNA-mediated double mutation assay. 
The 1757A mutation is approximately 50% less prone to the inhibitory effect of the clamp than the HBV 
WT (Figure 35). The melting profile displayed a distinct Tm for 1757A next to 1762T/1764A mutation 
(Figure 33). This assures that the mutation at within the clamp region will not produce false positivity even 
if HBV 1757A escapes the inhibitory effect of the clamp in the assay. 
  
Ultimately, a sensitive and rapid PCR-based assay was developed for the detection of the HBV double 
mutation.  When coupled with the melting curve analysis, it presents a simple, rapid, one-step detection 
method with high sensitivity and specificity. This advantage demonstrates the opportunity to assay bodily 
fluids such as blood or urine where HBV WT is present at high levels.  
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VII. CONCLUSION 
 
Having developed an assay demonstrating increased sensitivity, this advantageous ability to mediate 
detection sensitivity such as through the use of LNA provides the outlook for detecting future cancer 
biomarkers in biological fluids. The robust melting curve analysis holds the potential for a rapid and an 
easy way to diagnose disease and the post PCR analysis capability that eliminates some of the current 
challenged and disadvantages of detection.  
 
This assay sensitivity presents the capability to detect specific mutation in the body fluids such as blood or 
urine where high amounts of HBV WT DNA are present and furthermore presents an exciting frontier in 
the minimally invasive or noninvasive diagnostic field for early detection. Recent studies have 
demonstrated this possibility of detecting tumor-derived molecules from body fluids for 
screening/diagnostic purposes [59]. Such a noninvasive screening method by using urine for tumor derived 
molecules provides an alternative solution to the current ineffective methods. The noninvasive nature of the 
testing also holds a powerful appeal to patients and their willingness to comply.  Such approaches can be 
seen in numerous early detection studies aiming for the common goal of detecting oncogenic DNA in 
biological fluids [21-23, 41].  
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Figure 36. Schematic illustration of the possible mechanism that generates cell-free DNA in urine  
 
 
 
Detecting tumor DNA in urine has been previously shown that the short length, tumor-derived DNA can be 
filtered through the kidney barrier and excreted into urine. Future work in the detection of the HBV double 
mutation will lie in this noninvasive testing as it provides numerous advantages; such as increasing 
compliance, reliability, and cost-effectiveness and be most pivotal in paving the outcome of such a urine-
based PCR assay for the screening of HBV induced HCC. 
 
 
Through the end of this testing, an LNA-clamp PCR assay is reported for the detection of HBV 
1762T/1764A double mutation. The use of hybridization probes coupled with post-PCR melting curve 
analysis provides a rapid, simple, one-step detection method displaying high sensitivity and specificity. 
This application can be further extended to detection of various HCC markers such as p53, APC, GSTP-1, 
etc.  The goal of this research is to improve prognosis of HCC survival through early. Undergoing efficient 
and effective screening during the early stages of HCC will significantly improve the chances of receiving 
effective and timely treatment and ensuring survival[24].  
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